Is Virax Biolabs Group Ltd (VRAX) Halal?
Shariah Screening — 5 Standards
Based on financial data from March 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 23.7% / 30% | 265.6% / 30% | 1.9% / 30% | 271.41% / 5% | ✗ NOT HALAL |
| DJIM | 23.7% / 33% | 265.6% / 33% | 1.9% / 33% | 271.41% / 5% | ✗ NOT HALAL |
| MSCI | 5.9% / 33% | 65.8% / 33% | 0.5% / 33% | 271.41% / 5% | ✗ NOT HALAL |
| S&P | 23.7% / 33% | 265.6% / 33% | 1.9% / 33% | 271.41% / 5% | ✗ NOT HALAL |
| FTSE | 5.9% / 33% | 65.8% / 33% | 0.5% / 50% | 271.41% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -160788.3% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -83.8% | |
| Return on Assets (ROA) | -48.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$5M |
| Free Cash Flow | -$5M |
| Total Debt | $377,004 |
| Debt-to-Equity | 10.6 |
| Current Ratio | 11.4 |
| Total Assets | $6M |
Price & Trading
| Last Close | $0.17 |
| 50-Day MA | $0.23 |
| 200-Day MA | $0.53 |
| Avg Volume | 292K |
| Beta | 1.7 |
|
52-Week Range
$0.15
| |
About Virax Biolabs Group Ltd (VRAX)
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary diagnostics under the ViraxVet brand. It also provides ViraxImmune, a T cell In vitro diagnostic device and wellness mobile application; and service, such as antibody engineering, custom peptides, protein sequencing, vaccine efficacy testing, immunology lab services, kits and reagents. In addition, the company is involved in research and development activities; and provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, corporations, independent laboratories, large hospital systems and public and private institutions, as well as distributor customers. The company operates in the United Kingdom, the United States, and China. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Virax Biolabs Group Ltd (VRAX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Virax Biolabs Group Ltd is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Virax Biolabs Group Ltd's debt ratio?
Virax Biolabs Group Ltd's debt ratio is 23.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 5.9%.
What are Virax Biolabs Group Ltd's key financial metrics?
Virax Biolabs Group Ltd has a market capitalization of $1M, and revenue of $6,331. Return on equity stands at -83.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.